Accelerated Biosciences and Portugal-based CDMO Stemmatters have inked a strategic partnership aimed at codeveloping and comarketing human induced pluripotent stem cells (iPSC) derived from human trophoblast stem cells (hTSC).
According to Accelerated Bio, hTSCs represent the earliest-stage, pre-implantation, pluripotent stem cells that are ethically sourced. iPSC reprogrammed from hTSC would offer better characteristics than those from adult somatic cells.
The deal, which marks Accelerated Bio’s entry into the EU market, will involve using the California-based biotech’s hTSC platform to deliver iPSC derived from the earliest-stage material, creating an optimal foundation for regenerative medicine. The partners aim to establish capabilities to develop and manufacture hTSC-derived iPSC compliant with EU regulatory requirements, offering the iPSC platform to the European community and developing new treatment options for patients.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!